MCE 的所有产品仅用作科学研究，我们不为任何个人用途提供产品和服务。

BFH772

CAS No. : 890128-81-1

MCE 站：BFH772

产品活性：BFH772 是一种口服有效的 VEGFR2 抑制剂，IC₅₀ 为 3 nM。

研究领域：Protein Tyrosine Kinase/RTK

作用靶点：VEGFR

In Vitro: BFH772 is highly selective; apart from inhibiting VEGFR2 at 3 nM IC₅₀, it also targets B-RAF, RET, and TIE-2, albeit with at least 40-fold lower potency. BFH772 is inactive (IC₅₀>10 μM; >2 μM for cKIT) against all other tyrosine specific- and serine/threonine-specific protein kinases tested. BFH772 inhibits VEGFR2 with IC₅₀ of 4.6±0.6 nM in CHO cells. BFH772 inhibits VEGFR2 with IC₅₀ of 3 nM in HUVEC cells. BFH772 inhibits the ligand induced autophosphorylation of RET, PDGFR, and KIT kinases, with IC₅₀ values ranging between 30 and 160 nM. BFH772 is selective (IC₅₀ values >0.5 μM) against the kinases of EGFR, ERBB2, INS-R, and IGF-1R and against the cytoplasmic BCR-ABL kinase. IC₅₀ of BFH772 (<0.01 nM, n=2) demonstrates that they abrogated VEGF induced proliferation at remarkably low nM concentrations.

In Vivo: BFH772 at 3 mg/kg orally dosed once per day potently inhibits melanoma growth (by 54-90% for primary tumor and 71-96% for metastasis growth) as depicted by treatment to control ratios. Dose–response curves of BFH772 at 0.3, 1, and 3 mg/kg demonstrate that even at the lowest concentrations, this naphthalene-1-carboxamide inhibits VEGF induced tissue weight and TIE-2 levels but only reaches statistical significance at 1 mg/kg and above.

相关产品：Drug Repurposing Compound Library  |  Reprogramming Compound Library  |  Kinase Inhibitor Library  |  Differentiation Inducing Compound Library  |  Clinical Compound Library  |  Clinical Compound Library Plus  |  Anti-COVID-19 Compound Library  |  Protein Tyrosine Kinase Compound Library  |  Anti-Cancer Compound Library  |  Drug Repurposing Compound Library Plus  |  Bioactive Compound Library Plus  |  Sorafenib  |  Lenvatinib  |  Nintedanib  |  Regorafenib  |  Cabozantinib  |  Bevacizumab  |  Sunitinib  |  Ponatinib  |  Semaxinib  |  Apatinib  |  Axitinib  |  Pazopanib  |  Vandetanib  |  SU 5402  |  Cediranib  |  PD173074  |  RAF265  |  Foretinib  |  Ripretinib  |  5Z-7-Oxozeaenol  |  Tivozanib  |  Gandotinib  |  Sitravatinib  |  Lucitanib  |  SAR131675  |  Linifanib

品牌介绍:
•   MCE (MedChemExpress) 拥有数百种全球独家化合物，我们致力于为全球科研客户提供*新*全的高品质小分子活性化合物；
•   10,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领域；
•   设有专业的实验中心和严格的质控、验证体系；
•   提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；
•   产品的生物活性多经各国客户实验验证；
•   Nature, Cell, Science 等多种期刊及制药收录了MCE客户的科研成果；
•   专业团队跟踪*新的制药及生命科学研究进展，为您提供全球*新的活性化合物；
•   与世界各大制药公司及知名科研机构建立了长期的合作。